Prices For Specialty Drugs Growing Faster Than Inflation, AARP Says
Twenty-three of the top 25 specialty drugs used by Medicare Part D beneficiaries had price increases exceeding the general rate of inflation in 2007, according to an "Rx Watchdog Report" published by the AARP Public Policy Institute
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.